S Patrick Walton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7998918/publications.pdf

Version: 2024-02-01

41 1,127 16 32 g-index

43 43 43 43 1282

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Metal–Organic Frameworks for Drug Delivery: A Design Perspective. ACS Applied Materials & Samp; Interfaces, 2021, 13, 7004-7020.	8.0	435
2	Motivation in transition: Development and roles of expectancy, task values, and costs in early college engineering Journal of Educational Psychology, 2019, 111, 1081-1102.	2.9	78
3	Designing highly active siRNAs for therapeutic applications. FEBS Journal, 2010, 277, 4806-4813.	4.7	71
4	Impact of target mRNA structure on siRNA silencing efficiency: A largeâ€scale study. Biotechnology and Bioengineering, 2008, 100, 744-755.	3.3	56
5	Thermodynamic and Kinetic Characterization of Antisense Oligodeoxynucleotide Binding to a Structured mRNA. Biophysical Journal, 2002, 82, 366-377.	0.5	55
6	Recognition of siRNA Asymmetry by TAR RNA Binding Protein. Biochemistry, 2010, 49, 3148-3155.	2.5	44
7	Prediction of antisense oligonucleotide binding affinity to a structured RNA target. Biotechnology and Bioengineering, 1999, 65, 1-9.	3.3	41
8	Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals, 2013, 6, 440-468.	3.8	33
9	Emerging affinity-based techniques in proteomics. Expert Review of Proteomics, 2009, 6, 573-583.	3.0	26
10	Development of a dual-aptamer-based multiplex protein biosensor. Biosensors and Bioelectronics, 2010, 25, 2663-2668.	10.1	24
11	Brain derived neurotrophic factor release from layer-by-layer coated agarose nerve guidance scaffolds. Acta Biomaterialia, 2015, 18, 128-131.	8.3	23
12	In vitro binding of singleâ€stranded RNA by human Dicer. FEBS Letters, 2007, 581, 5611-5616.	2.8	20
13	Rational selection and quantitative evaluation of antisense oligonucleotides. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1520, 105-114.	2.4	19
14	Prediction of antisense oligonucleotide binding affinity to a structured RNA target. Biotechnology and Bioengineering, 1999, 65, 1-9.	3.3	19
15	Confocal microscopy for the analysis of siRNA delivery by polymeric nanoparticles. Microscopy Research and Technique, 2010, 73, 878-885.	2.2	16
16	Latest developments in experimental and computational approaches to characterize protein–lipid interactions. Proteomics, 2012, 12, 3273-3285.	2.2	16
17	Endocytosis Controls siRNA Efficiency: Implications for siRNA Delivery Vehicle Design and Cell-Specific Targeting. Nucleic Acid Therapeutics, 2020, 30, 22-32.	3.6	16
18	Improved asymmetry prediction for short interfering <scp>RNA</scp> s. FEBS Journal, 2014, 281, 320-330.	4.7	14

#	Article	IF	CITATIONS
19	Effect of siRNA terminal mismatches on TRBP and Dicer binding and silencing efficacy. FEBS Journal, 2009, 276, 6576-6585.	4.7	13
20	Dextran functionalization enhances nanoparticle-mediated siRNA delivery and silencing. Technology, 2016, 04, 42-54.	1.4	13
21	Coupling of inflammatory cytokine signaling pathways probed by measurements of extracellular acidification rate. Biophysical Chemistry, 2001, 89, 1-12.	2.8	11
22	Application and analysis of structure-switching aptamers for small molecule quantification. Analytica Chimica Acta, 2009, 638, 213-219.	5.4	11
23	Palmitate-Induced IRE1–XBP1–ZEB Signaling Represses Desmoplakin Expression and Promotes Cancer Cell Migration. Molecular Cancer Research, 2021, 19, 240-248.	3.4	11
24	Molecular Mechanism by Which Palmitate Inhibits PKR Autophosphorylation. Biochemistry, 2011, 50, 1110-1119.	2.5	10
25	Quantitative, solution-phase profiling of multiple transcription factors in parallel. Analytical and Bioanalytical Chemistry, 2013, 405, 2461-2468.	3.7	9
26	ENDOCYTOSIS PATHWAYS FOR NUCLEIC ACID THERAPEUTICS. Nano LIFE, 2012, 02, 1241005.	0.9	8
27	Synergy Analysis Reveals Association between Insulin Signaling and Desmoplakin Expression in Palmitate Treated HepG2 Cells. PLoS ONE, 2011, 6, e28138.	2.5	6
28	Analysis of hybridization on the molecular barcode GeneChip microarray. Biochemical and Biophysical Research Communications, 2006, 348, 689-696.	2.1	5
29	The multiplicative function of expectancy and value in predicting engineering students' choice, persistence, and performance. Journal of Engineering Education, 2022, 111, 531-553.	3.0	5
30	Terminal Duplex Stability and Nucleotide Identity Differentially Control siRNA Loading and Activity in RNA Interference. Nucleic Acid Therapeutics, 2016, 26, 309-317.	3.6	3
31	Characterization of transcription factor response kinetics in parallel. BMC Biotechnology, 2016, 16, 62.	3.3	2
32	Use of Brevibacillus choshinensis for the production of biologically active brain-derived neurotrophic factor (BDNF). Applied Microbiology and Biotechnology, 2017, 101, 5645-5652.	3.6	2
33	Instructional Supports for Motivation Trajectories in Introductory College Engineering. AERA Open, 2022, 8, 233285842210836.	2.1	2
34	Engineering active siRNA therapeutics. FEBS Journal, 2010, 277, 4805-4805.	4.7	1
35	How can novel microscopic approaches shed light on the function of nucleic acid-based drugs?. Future Medicinal Chemistry, 2015, 7, 1623-1625.	2.3	1
36	Relative Quantification of siRNA Strand Loading into Ago2 for Design of Highly Active siRNAs. Methods in Molecular Biology, 2019, 1974, 41-56.	0.9	1

S PATRICK WALTON

#	Article	IF	CITATIONS
37	Biological network analyses: computational genomics and systems approaches. Molecular Simulation, 2006, 32, 203-209.	2.0	0
38	Engineering Cell Function by RNA Interference. Cell Engineering, 2009, , 175-194.	0.4	0
39	Kinetic analysis of the intracellular processing of siRNAs by confocal microscopy. Microscopy (Oxford, England), 2020, 69, 401-407.	1.5	O
40	Modulating Polymer-siRNA Binding Does Not Promote Polyplex-Mediated Silencing. Nucleic Acid Therapeutics, 2021, 31, 229-236.	3.6	0
41	Biomolecular Engineering in Oligonucleotide Applications. The Electrical Engineering Handbook, 2006, , 17-1-17-20.	0.2	0